Intravitreal voriconazole: In vitro safety-profile for fungal endophthalmitis

Retina

Volumn 29, Issue 3, 2009, Pages 362-370

  Kernt, Marcus ^a   Neubauer, Aljoscha S ^a   De Kaspar, Herminia Mino ^a,b   Kampik, Anselm ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; VORICONAZOLE;

ARTICLE; ASTROCYTE; CELL PROLIFERATION; CELL VIABILITY; COLORIMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SAFETY; EPITHELIUM CELL; FUNGAL ENDOPHTHALMITIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INFLAMMATION; MICROSCOPY; OPTIC NERVE; OXIDATIVE STRESS; PIGMENT EPITHELIUM; QUANTITATIVE ANALYSIS;

ADULT; AGED; ANTIFUNGAL AGENTS; CELL PROLIFERATION; CELLS, CULTURED; COLORIMETRY; ENDOPHTHALMITIS; EYE INFECTIONS, FUNGAL; HUMANS; INJECTIONS; MIDDLE AGED; OXIDATIVE STRESS; PYRIMIDINES; RETINAL PIGMENT EPITHELIUM; TREATMENT OUTCOME; TRIAZOLES; VITREOUS BODY;

EID: 67749090958     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31818d4b9b     Document Type: Article

References (60)

1. Benz MS, Scott IU, Flynn HW Jr, Unonius N, Miller D. Endophthalmitis isolates and antibiotic sensitivities: a 6-year review of culture-proven cases. Am J Ophthalmol 2004;137: 38-42.
2. Marangon FB, Miller D, Giaconi JA, Alfonso EC. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens. Am J Ophthalmol 2004; 137:820-825.
3. Donahue SP. Intraocular candidiasis in patients with candidemia. Ophthalmology 1998;105:759-760.
4. Narang S, Gupta A, Gupta V, et al. Fungal endophthalmitis following cataract surgery: clinical presentation, microbiological spectrum, and outcome. Am J Ophthalmol 2001;132:609-617.
5. Schiedler V, Scott IU, Flynn HW Jr, Davis JL, Benz MS, Miller D. Culture-proven endogenous endophthalmitis: clinical features and visual acuity outcomes. Am J Ophthalmol 2004;137:725-731.
6. Kattan HM, Flynn HW Jr, Pflugfelder SC, Robertson C, Forster RK. Nosocomial endophthalmitis survey. Current incidence of infection after intraocular surgery. Ophthalmology 1991;98:227-238.
7. Breit SM, Hariprasad SM, Mieler WF, Shah GK, Mills MD, Grand MG. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol 2005;139:135-140.
8. Essman TF, Flynn HW Jr, Smiddy WE, et al. Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis. Ophthalmic Surg Lasers 1997;28:185-194.
9. Axelrod AJ, Peyman GA, Apple DJ. Toxicity of intravitreal injection of amphotericin B. Am J Ophthalmol 1973;76:578-583.
10. Souri EN, Green WR. Intravitreal amphotericin B toxicity. Am J Ophthalmol 1974;78:77-81.
11. Clements JS Jr, Peacock JE Jr. Amphotericin B revisited: reassessment of toxicity. Am J Med 1990;88:22N-27N.
12. O'Day DM, Foulds G, Williams TE, Robinson RD, Allen RH, Head WS. Ocular uptake of fluconazole following oral administration. Arch Ophthalmol 1990;108:1006 -1008.
13. Wellington M, Gigliotti F. Update on antifungal agents. Pediatr Infect Dis J 2001;20:993-995.
14. Shahsavari M, Peyman GA, Niesman MR. Retinal toxicity and in vitro efficacy study of cilofungin (LY121019). Ophthalmic Surg 1990;21:726 -728.
15. Serracarbassa PD, Peyman GA, Liang C, Calixto N Jr, Nair MG. Toxicity and efficacy of intravitreal injection of spartanamicin B in the treatment of Candida endophthalmitis. Int Ophthalmol 1998;22:53-58.
16. Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 2001;150:101-115.
17. Herbrecht R. Voriconazole: therapeutic review of a new azole antifungal. Expert Rev Anti Infect Ther 2004;2:485-497.
18. Perea JR, Diaz De Rada BS, Quetglas EG, Juarez MJ. Oral versus intravenous therapy in the treatment of systemic mycosis. Clin Microbiol Infect 2004;10:96-106.
19. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003;37:728-732.
20. Haritoglou C, Yu A, Freyer W, et al. An evaluation of novel vital dyes for intraocular surgery. Invest Ophthalmol Vis Sci 2005;46:3315-3322.
21. Yu AL, Fuchshofer R, Birke M, et al. Hypoxia/reoxygenation and TGF-beta increase alpha B-crystallin expression in human optic nerve head astrocytes. Exp Eye Res 2007;84:694-706.
22. Kernt M, Neubauer AS, Ulbig MW, Kampik A, Welge-Lüßen U. In vitro safety of intravitreal moxifloxacin for endophthalmitis treatment. J Cataract Refract Surg 2008;34:480-488.
23. Ramadan RT, Ramirez R, Novosad BD, Callegan, MC. Acute inflammation and loss of retinal architecture and function during experimental Bacillus endophthalmitis. Curr Eye Res 2006;31:955-965.
24. Hoshino K, Takeuchi O, Kawai T, et al. Cutting edge: toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipo-polysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999;162:3749-3752.
25. Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 1994;45:491-503.
26. Feys J, Emond JP, Salvanet-Bouccara A, Dublanchet A. In-terleukin-6 and other cytokines in the aqueous humor in uveitis and endophthalmitis. J Fr Ophtalmol 1994;17:634-639.
27. Giese MJ, Sumner HL, Berliner JA, Mondino BJ. Cytokine expression in a rat model of Staphylococcus aureus endophthalmitis. Invest Ophthalmol Vis Sci 1998;39:2785-2790.
28. Kameda H, Fujiwara H, Katayama T, Suzuki T, Egi K, Goto S. Anaphylatoxin in the aqueous humor of rabbit with endotoxin induced endophthalmitis. Nippon Ganka Gakkai Zasshi 1989; 93:22-27.
29. Alge CS, Priglinger SG, Neubauer AS, et al. Retinal pigment epithelium is protected against apoptosis by alphaB-crystallin. Invest Ophthalmol Vis Sci 2002;43:3575-3582.
30. Yang J, Yang P, Tezel G, Patil RV, Hernandez MR, Wax MB. Induction of HLA-DR expression in human lamina cribrosa astrocytes by cytokines and simulated ischemia. Invest Oph-thalmol Vis Sci 2001;42:365-371.
31. Satofuka S, Ichihara A, Nagai N, et al. Suppression of ocular inflammation in endotoxin-induced uveitis by inhibiting non-proteolytic activation of prorenin. Invest Ophthalmol Vis Sci 2006;47:2686 -2692.
32. Thomas J, Kanangat S, Rouse BT. Herpes simplex virus replication-induced expression of chemokines and proinflammatory cytokines in the eye: implications in herpetic stromal keratitis. J Interferon Cytokine Res 1998;18:681-690.
33. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
34. Keswani T, Ahuja V, Changulani M. Evaluation of outcome of various treatment methods for endogenous endophthalmitis. Indian J Med Sci 2006;60:454-460.
35. Wykoff CC, Flynn HW Jr, Miller D, Scott IU, Alfonso EC. Exogenous fungal endophthalmitis: microbiology and clinical outcomes. Ophthalmology 2008;115:1501-1507.
36. Kramer M, Kramer MR, Blau H, Bishara J, Axer-Siegel R, Weinberger D. Intravitreal voriconazole for the treatment of endogenous Aspergillus endophthalmitis. Ophthalmology 2006;113:1184-1186.
37. Brod RD, Flynn HW Jr, Clarkson JG, Pflugfelder SC, Culbert-son WW, Miller D. Endogenous Candida endophthalmitis. Management without intravenous amphotericin B. Ophthalmology 1990;97:666-672.
38. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12:308-329.
39. McKelvie PA, Wong EY, Chow LP, Hall AJ. Scedosporium endophthalmitis: two fatal disseminated cases of Scedospo-rium infection presenting with endophthalmitis. Clin Experiment Ophthalmol 2001;29:330-334.
40. Ghannoum MA, Kuhn DM. Voriconazole-better chances for patients with invasive mycoses. Eur J Med Res 2002;7:242-256.
41. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999;12: 501-517.
42. Sabo JA, Abdel-Rahman SM. Voriconazole: a new triazole antifungal. Ann Pharmacother 2000;34:1032-1043.
43. Sanati H, Belanger P, Fratti R, Ghannoum M. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother 1997;41:2492-2496.
44. Sen P, Gopal L, Sen PR. Intravitreal voriconazole for drug-resistant fungal endophthalmitis: case series. Retina 2006;26: 935-939.
45. Nehemy MB, Vasconcelos-Santos DV, Torqueti-Costa L, Magalhaes EP. Chronic endophthalmitis due to verticillium species after cataract surgery treated (or managed) with pars plana vitrectomy and oral and intravitreal voriconazole. Retina 2006; 26:225-227.
46. Durand ML, Kim IK, D'Amico DJ, et al. Successful treatment of Fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin. Am J Ophthalmol 2005;140:552-554.
47. Figueroa MS, Fortun J, Clement A, De Arevalo BF. Endogenous endophthalmitis caused by Scedosporium apiospermum treated with voriconazole. Retina 2004;24:319 -320.
48. Yoshida T, Jono K, Okonogi K. Modified agar dilution susceptibility testing method for determining in vitro activities of antifungal agents, including azole compounds. Antimicrob Agents Chemother 1997;41:1349-1351.
49. Therese KL, Bagyalakshmi R, Madhavan HN, Deepa P. In-vitro susceptibility testing by agar dilution method to determine the minimum inhibitory concentrations of amphotericin B, fluconazole and ketoconazole against ocular fungal isolates. Indian J Med Microbiol 2006;24:273-279.
50. Kernt M, Welge-Lussen U, Yu A, Neubauer AS, Kampik A. Bevacizumab is not toxic to human anterior- and posterior-segment cultured cells. Ophthalmologe 2007;104:965-971.
51. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003;36:630-637.
52. Pfaller MA, Messer SA, Hollis RJ, et al. In vitro susceptibilities of Candida bloodstream isolates to the new triazole anti-fungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob Agents Chemother 1998;42:3242-3244.
53. Kappe R. Antifungal activity of the new azole UK-109 496 (voriconazole): addition and clarification. Mycoses 2001;44:432.
54. Maesaki S, Iwakawa J, Higashiyama Y, et al. Antifungal activity of a new triazole, voriconazole (UK-109496), against clinical isolates of Aspergillus spp. J Infect Chemother 2000; 6:101-103.
55. Hariprasad SM, Mieler WF, Holz ER, et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol 2004;122:42-47.
56. Zarkovic A, Guest S. Scedosporium apiospermum traumatic endophthalmitis successfully treated with voriconazole. Int Ophthalmol 2007;27:391-394.
57. Nehemy MB, Vasconcelos-Santos DV, Torqueti-Costa L, Ma-galhaes EP. Chronic endophthalmitis due to verticillium species after cataract surgery treated (or managed) with pars plana vitrectomy and oral and intravitreal voriconazole. Retina 2006; 26:225-227.
58. Gao H, Pennesi ME, Shah K, et al. Intravitreal voriconazole: an electroretinographic and histopathologic study. Arch Ophthalmol 2004;122:1687-1692.
59. Wakiec R, Prasad R, Morschhauser J, Barchiesi F, Borowski E, Milewski S. Voriconazole and multidrug resistance in Candida albicans. Mycoses 2007;50:109-115.
60. Sutton DA, Sanche SE, Revankar SG, Fothergill AW, Rinaldi MG. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to vori-conazole. J Clin Microbiol 1999;37:2343-2345.